Polypill in Cardiovascular Disease Prevention: Efficacy and Perspectives
Abstract
Cardiovascular diseases (CVDs) are among the leading causes of morbidity and mortality worldwide. To enhance the effectiveness of prevention, the concept of a polypill containing multiple active pharmaceutical components has been introduced. This review explores the role of the polypill in primary and secondary prevention, along with its advantages and limitations. In primary prevention, the polypill may help reduce the risk of developing hypertension, dyslipidemia, and thrombosis. In secondary prevention, it aids in lowering the likelihood of recurrent cardiovascular events such as myocardial infarction and stroke. Additionally, the polypill improves medication adherence and reduces overall healthcare costs
About the Authors
List of references
B. Williams, S. Masi, J. Wolf, and R. E. Schmieder, «Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension», Cardiol. Ther., 9, issue. 1, . 19–34, Jun. 2020, https://doi.org/10.1007/s40119-019-00159-1.
W. P. Castelli and K. Anderson, «A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the framingham study», Am. J. Med., 80, issue. 2, . 23–32, . 1986, https://doi.org/10.1016/00 02-9343(86)90157-9.
«Serum Cholesterol, Blood Pressure, Cigarette Smoking, and Death From Coronary Heart Disease: Overall Findings and Differences by Age for 316099 White Men for the Multiple Risk Factor Intervention Trial Research Group Biostatistics Research output: Contribution to journal › Article › peer-review».
S. Yusuf and ., «Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study».
D. Zanetti, S. Gustafsson, T. L. Assimes, and E. Ingelsson, «Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events», Circ. Genomic Precis. Med., 13, issue. 6, . 2020, https://doi.org/10.1161/CIRCGEN.120.002996.
«Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease Brian A Ference 1,2,, Deepak L Bhatt 3, Alberico L Catapano 4, Chris J Packard 5, Ian Graham 6, Stephen Kaptoge 2, Thatcher B Ference 1, Qi Guo 1,2, Ulrich Laufs 7, Christian T Ruff 8, Arjen Cupido 1,9, G Kees Hovingh 9, John Danesh 2, Michael V Holmes 10, George Davey Smith 11, Kausik K Ray 12, Stephen J Nicholls 13, Marc S Sabatine 8».
N. J. Wald, «A strategy to reduce cardiovascular disease by more than 80%», BMJ, 326, issue. 7404, . 1419–0, Jun. 2003, https://doi.org/10.1136/bmj.326.7404.1419.
«Toole JF, Malinow MR, Chambless LE, et al. Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA. 2004;291(5):565–575. doi:10.1001/jama.291.5.565».
S. Mairesse and J. Blacher, «Homocysteine lowering with folic acid and B vitamins in vascular disease, The Heart Outcomes Prevention Evaluation (HOPE) 2 investigators», J. Mal. Vasc., 31, issue. 4, . 221–222,
. 2006, https://doi.org/10.1016/S0398-0499(06)76550-7.
R. Waring, «Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction», N Engl J Med, 2006.
«Danchin N., Cambou J.P., Hanania G. et al. Impact of combined secondary pre- vention therapy after myocardial infarction: data from a nationwide French regist- ry. Am Heart J. 2005; 150: 1147–1153.»
Ferrer International. Trinomia® 100 mg/40 mg/5 mg SmPC. Available at: https://cima.aemps.es/cima/ pdfs/ft/81774/FT_81774.pdf December 2022
J. M. Castellano and ., «Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study», Arch. Med. Res., 50, issue. 1, . 31–40, Jan. 2019, https://doi.org/10.1016/j.arcmed.2019.04.001.
E. Gómez-Álvarez, J. Verdejo, S. Ocampo, C. I. Ponte-Negretti, E. Ruíz, and M. M. Ríos, «The CNIC- polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico», IJC Heart Vasc., 29, . 100545, Aug. 2020, https://doi.org/ 10.1016/j.ijcha.2020.100545.
E. Gómez-Álvarez, J. Verdejo, S. Ocampo, E. Ruiz, M. A. Martinez-Rios, and On behalf of the SORS investigators, «Reaching Blood Pressure Guideline Targets With the CNIC Polypill in Patients With a Previous Cardiovascular Event in Mexico: A post hoc Analysis of the Sors Study», Future Cardiol., 16, issue. 1, . 53–60, Jan. 2020, https://doi.org/10.2217/fca-2019-0075.
J. M. Castellano and ., «Polypill Strategy in Secondary Cardiovascular Prevention», N. Engl. J. Med., 387, issue. 11, . 967–977, . 2022, https://doi.org/10.1056/NEJMoa2208275.
"Gonzalez-Juanatej J.R., Cordero A, Castellano J. M.,Masana L,Dalmau R,Ruiz E, Sicras-Mainar A,Fuster V.CNIC-polypill reduces the frequency of repeated serious cardiovascular events in real patients undergoing secondary prevention in Spain: a NEPTUNO study.Int J Cardiol 2022;361:116-123."
R. Dalmau, A. Cordero, L. Masana, E. Ruiz, A. Sicras-Mainar, and J. R. González-Juanatey, «The CNIC- polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease», Eur. Heart J. Open, 4, issue. 2, . oeae027, mar. 2024, https://doi.org/10.1093/ehjopen/oeae027.
C. Aguiar and ., «Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study», J. Health Econ. Outcomes Res., . 134–146, . 2022, https://doi.org/10.36469/jheor.2022.39768.
w A. Cordero and ., «Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study», Clin. Outcomes Res., Volume 15, . 559–571, . 2023, https://doi.org/10.2147/CEOR.S396290.
A. González-Domínguez, A. Durán, Á. Hidalgo-Vega, and V. Barrios, «Cost-effectiveness of the CNIC- Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain», Rev. Clínica Esp. Engl. Ed., 223, issue. 7, . 414–422, Aug. 2023, https://doi.org/10.1016/j.rceng.2023.06.007.
B. Franczyk, A. Gluba-Brzózka, Ł. Jurkiewicz, P. Penson, M. Banach, and J. Rysz, «Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?», Expert Opin. Pharmacother., 19, issue. 17, . 1857–1865, . 2018, https://doi.org/10.1080/14656566.2018.1532501.
S. Birla and ., «Redefining the polypill: pros and cons in cardiovascular precision medicine», Front. Pharmacol., T. 14, c. 1268119, . 2023, https://doi.org/10.3389/fphar.2023.1268119.
«Konyi, A., et al. „Effectiveness and safety of combined antihypertensive and cholesterol-reducing therapy (lisinopril-amlodipine and rosuvastatin) in high and very high risk patient populations.“ Cardiologia Hungarica 45 (2015): 71.»
«Emerging Risk Factors Collaboration et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis //The Lancet. – 2010. – 375. – №. 9709. – . 132-140.»
J. Charan, J. P. Goyal, and D. Saxena, «Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis», J. Cardiovasc. Dis. Res., 4, issume. 2, . 92–97, Jun. 2013, https://doi.org/10.1016/j. jcdr.2012.11.005.
«Yusuf, S., et al. „Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle- aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.“ Lancet 373.9672 (2009): 1341-1351.»
«Kim, J. H., Zamorano, J., Erdine, S., Pavia, A., Al-Khadra, A., Sutradhar, S. (2012). Proactive Cardiovascular Risk Management versus Usual Care in Patients with and without Diabetes Mellitus: CRUCIAL Trial Subanalysis. Postgraduate Medicine, 124(4), 41–53. https://doi.org/10.3810/pgm.2012.0 7.2565».
J. Al Suwaidi, «Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings», Glob. Cardiol. Sci. Pract., 2016, issue. 2, Oct. 2016, https://doi.org/10.215 42/gcsp.2016.13.
S. Thom, «Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD: The UMPIRE Randomized Clinical Trial", JAMA, vol. 310, issue 9, p. 918, Sep. 2013, https://doi.org/10.1001/jama.2013.277064.
«Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology. 2015;22(7):920-930. https://doi.org/10.1177/2047487314530382».
J. M. Castellano et al., "Polypill Strategy in Secondary Cardiovascular Prevention", N. Engl. J. Med., vol. 387, issue 11, pp. 967-977, sep. 2022, https://doi.org/10.1056/NEJMoa2208275.
J. M. Castellano et al., "A Polypill Strategy to Improve Adhesion", J. Am. Coll. Cardiol., vol. 64, issue 20, pp. 2071-2082, Nov. 2014, https://doi.org/10.1016/j.jack.2014.08.021.
"Lafeber M. et al. "Comparison of a morning polytableted drug, an evening polytableted drug, and individual pills on the effects on LDL cholesterol, outpatient blood pressure, and treatment adherence in high-risk patients; a randomized cross-sectional study." International Journal of Cardiology 181 (2015): 193-199."
«2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults».
«Blood Pressure Lowering Treatment Trialists’ Collaboration et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data //The Lancet. – 2014. – 384. – №. 9943. – . 591-598.»
E. M. Lonn et al., "Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease", N. Engl. J. Med., vol. 374, issue 21, pp. 2009-2020, May 2016, https://doi.org/10.1056/ NEJMoa1600175.
A. N. De Kates et al., "Fixed-dose combination therapy for the prevention of cardiovascular diseases", Cochrane Database of Systematic Reviews, Cochrane Collaboration, ed., Chichester, UK: John Wiley Sons, Ltd, 2014, pp. CD009868.pub2. https://doi.org/10.1002/14651858.CD009868.publication2.
Copyright (c) 2025 Ш.С. Файзуллаев, Г.А. Хамидуллаева, Г.Дж. Абдуллаева, Х.Ф. Юсупова (Автор)
This work is licensed under a Creative Commons Attribution 4.0 International License.